Bill > SCR227

This Concurrent Resolution requests the Department of Health to establish a Medicinal Psilocybin and Psilocin Working Group to investigate the potential medical and therapeutic benefits of psilocybin and psilocin, which are naturally occurring chemicals found in certain mushrooms that affect brain receptors and have shown promise in treating various mental health conditions like depression and anxiety. The working group, composed of various stakeholders including health officials, legal representatives, university faculty, and community members, is tasked with reviewing existing laws and research on these substances and, if possible, developing a comprehensive long-term plan to ensure that medicinal psilocybin and psilocin products are safe, accessible, and affordable for eligible adults aged 21 and older. The group is required to submit preliminary findings by early 2023 and a final report with legislative proposals by early 2024, after which it will be dissolved.